Lisa Marie Reindl

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 6

Top Topics

Cell Proliferation

Top Venues

Journal of molecular medicine (Berlin, Germany)

Cell death discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Vinzenz Särchen, Lisa Marie Reindl, Sara Wiedemann, Senthan Shanmugalingam, Thomas Bukur, Julia Becker, Martin Suchan, Evelyn Ullrich, Meike Vogler
Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids. Cells 12 (6) (2023)
Vinzenz Särchen, Lisa Marie Reindl, Sara Wiedemann, Senthan Shanmugalingam, Thomas Bukur, Julia Becker, Martin Suchan, Evelyn Ullrich, Meike Vogler
Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids. Cells 12 (6) (2023)
Vinzenz Särchen, Lisa Marie Reindl, Sara Wiedemann, Senthan Shanmugalingam, Thomas Bukur, Julia Becker, Martin Suchan, Evelyn Ullrich, Meike Vogler
Characterization of BV6-Induced Sensitization to the NK Cell Killing of Pediatric Rhabdomyosarcoma Spheroids. Cells 12 (6) (2023)
Vinzenz Särchen, Senthan Shanmugalingam, Sarah Kehr, Lisa Marie Reindl, Victoria Greze, Sara Wiedemann, Cathinka Boedicker, Maureen Jacob, Katrin Bankov, Nina Becker, Sibylle Wehner, Till M Theilen, Steffen Gretser, Elise Gradhand, Carsten Kummerow, Evelyn Ullrich, Meike Vogler
Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy. Cell death discovery 8 (1) (2022)
Philipp Wendel, Lisa Marie Reindl, Tobias Bexte, Leander Künnemeyer, Vinzenz Särchen, Nawid Albinger, Andreas Mackensen, Eva Rettinger, Tobias Bopp, Evelyn Ullrich
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy. Cancers 13 (6) (2021)
Meike Vogler, Senthan Shanmugalingam, Vinzenz Särchen, Lisa Marie Reindl, Victoria Grèze, Leon Buchinger, Michael Kühn, Evelyn Ullrich
Unleashing the power of NK cells in anticancer immunotherapy. Journal of molecular medicine (Berlin, Germany) (2021)